Osborne Clarke has advised TRiCares SAS on its €22m Series B financing round. Proceeds from the financing will be used to advance product development, conduct clinical trials and to gain CE registration in Europe.
The financing round was led by incoming investors Wellington Partners, Germany, Andera Partners, France, and BioMed Partners, Switzerland and the existing French syndicate of CM-CIC Innovation, CapDecisif Management and GO Capital.
Founded in 2013, TRiCares is a medical device start-up company headquartered in Paris, France, with an operating location in Munich. The company’s vision is to bring to the market a transcatheter based tricuspid valve replacement system to help patients suffering from severe tricuspid regurgitation, without the need for open heart surgery.
An Osborne Clarke team led by Tim Reinhard advised TRiCares on the investment. The team included Mark Friedrich (Corporate/Munich), Piet Weinreich (IP/Munich) and Catherine Olive (Corporate) from Osborne Clarke's Paris office.